KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Cash from Investing Activities (2016 - 2025)

Biogen has reported Cash from Investing Activities over the past 17 years, most recently at -$1.2 billion for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$1.2 billion for Q4 2025, down 6522.04% from a year ago — trailing twelve months through Dec 2025 was -$1.4 billion (down 71.56% YoY), and the annual figure for FY2025 was -$1.4 billion, down 71.56%.
  • Cash from Investing Activities for Q4 2025 was -$1.2 billion at Biogen, down from -$35.1 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for BIIB hit a ceiling of $1.7 billion in Q3 2022 and a floor of -$1.7 billion in Q3 2023.
  • Median Cash from Investing Activities over the past 5 years was -$126.9 million (2021), compared with a mean of -$262.9 million.
  • Biggest five-year swings in Cash from Investing Activities: soared 815.84% in 2022 and later tumbled 6522.04% in 2025.
  • Biogen's Cash from Investing Activities stood at -$112.7 million in 2021, then decreased by 25.2% to -$141.1 million in 2022, then tumbled by 362.3% to -$652.3 million in 2023, then surged by 97.15% to -$18.6 million in 2024, then tumbled by 6522.04% to -$1.2 billion in 2025.
  • The last three reported values for Cash from Investing Activities were -$1.2 billion (Q4 2025), -$35.1 million (Q3 2025), and -$57.0 million (Q2 2025) per Business Quant data.